Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 ,inter alia, to consider and approve 1. Un-audited (Standalone ....
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs has informed BSE that its Board of Directors will meet on October 31, 2025 to consider and approve the unaudited standalone and consolidated financial results for Q2 and the half year ended September 30, 2025. The Board will also consider declaring a 2nd interim dividend for FY 2025-26, if applicable. Additionally, the Board will discuss the issuance of bonus shares, subject to shareholder approval. The trading window for dealing in the company's securities remains closed till November 2, 2025 in line with insider trading regulations.
This is a pre-results announcement — investors should watch for the actual Q2 numbers, any dividend declaration, and the bonus share proposal, all of which could influence the stock price post-announcement. A bonus issue, if approved, would increase share count and is typically viewed as a confidence signal from management.